Market Cap 235.34B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
EPS (ttm) N/A
PE Ratio 14.19
Forward PE 13.02
Profit Margin 23.09%
Debt to Equity Ratio 0.67
Volume 2,803,200
Avg Vol 2,499,906
Day's Range N/A - N/A
Shares Out 2.11B
Stochastic %K 84%
Beta 0.56
Analysts Sell
Price Target $115.88

Latest News on NVS

Novartis After Sandoz: The Business Without Generics

Apr 6, 2025, 6:38 AM EDT - 17 days ago

Novartis After Sandoz: The Business Without Generics


Novartis scraps use of diverse panels for hires in US

Mar 19, 2025, 8:45 AM EDT - 5 weeks ago

Novartis scraps use of diverse panels for hires in US


NFL signs Novartis as first pharmaceutical partner-source

Mar 13, 2025, 8:03 AM EDT - 5 weeks ago

NFL signs Novartis as first pharmaceutical partner-source


Final Trade: NVS, XLU, GM

Mar 5, 2025, 6:24 PM EST - 7 weeks ago

Final Trade: NVS, XLU, GM

GM XLU


Why Novartis Remains A 'Buy' After Beating Expectations Again

Feb 27, 2025, 10:09 AM EST - 7 weeks ago

Why Novartis Remains A 'Buy' After Beating Expectations Again


Novartis: Strong Execution With A P/E Discount

Feb 16, 2025, 12:02 AM EST - 2 months ago

Novartis: Strong Execution With A P/E Discount


Novartis: Just What The Doctor Ordered

Feb 14, 2025, 7:30 AM EST - 2 months ago

Novartis: Just What The Doctor Ordered


Novartis agrees to acquire Anthos for up to $3.1 bln

Feb 11, 2025, 1:41 AM EST - 2 months ago

Novartis agrees to acquire Anthos for up to $3.1 bln


Novartis AG (NVS) Q4 2024 Earnings Call Transcript

Jan 31, 2025, 12:20 PM EST - 2 months ago

Novartis AG (NVS) Q4 2024 Earnings Call Transcript


Novartis beats consensus on Q4 earnings

Jan 31, 2025, 1:14 AM EST - 2 months ago

Novartis beats consensus on Q4 earnings